目的 探讨咳露口服液联合酮替芬治疗咳嗽变异性哮喘的临床疗效和安全性。方法 选取2016年11月—2017年11月于洛阳市中心医院就诊的咳嗽变异性哮喘患者120例，随机分成对照组和治疗组，每组各60例。对照组口服富马酸酮替芬片，1片/次，2次/d；治疗组患者在对照组的基础上口服咳露口服液，15 mL/次，3次/d。两组患者均连续治疗2个月。观察两组患者临床疗效，同时比较治疗前后两组患者哮喘控制测试（ACT）评分、日常生活活动（ADL）评分、咳嗽症状积分、嗜酸性粒细胞（EOS）绝对值、肺功能和不良反应。结果 治疗后，对照组和治疗组临床有效率分别为81.67%和95.00%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者ACT和ADL评分显著升高（P<0.05），咳嗽症状积分显著降低（P<0.05），且治疗组患者ACT、ADL及咳嗽症状积分水平明显好于对照组（P<0.05）。治疗后，两组EOS绝对值显著降低（P<0.05），肺功能指标用力肺活量（FVC）和第1秒钟用力呼吸容积（FEV1）显著升高（P<0.05），且治疗组患者EOS绝对值及肺功能较对照组患者改善更明显（P<0.05）。治疗期间，治疗组患者不良反应发生率为3.33%，显著低于对照组的15.00%，两组比较差异具有统计学意义（P<0.05）。结论 咳露口服液联合酮替芬治疗咳嗽变异性哮喘疗效显著，安全性好，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy and safety of Kelu Oral Liquid combined with ketotifen in treatment of cough variant asthma. Methods Patients (120 cases) with cough variant asthma in Luoyang Central Hospital from November 2016 to November 2017 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were po administered with Ketotifen Fumarate Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Kelu Oral Liquid on the basis of the control group, 15 mL/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and ACT, ADL and cough symptom scores, absolute value of EOS, lung function and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 81.67% and 95.00%, respectively, and there were differences between two groups (P<0.05). After treatment, the ACT and ADL scores in two groups were significantly increased (P<0.05), but cough symptom scores were significantly decreased (P<0.05), and the ACT, ADL and cough symptom scores in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the absolute value of EOS in two groups was significantly decreased (P<0.05), but FVC and FEV1 levels were significantly increased (P<0.05), and the absolute value of EOS, lung function in the treatment group was significantly better than that in the control group (P<0.05). During the treatment, the adverse reactions rate in the treatment group was 3.33%, which was significantly lower than 15.00% in the control group, with significant difference between two groups (P<0.05). Conclusion Kelu Oral Liquid combined with ketotifen has significant curative effect in treatment of cough variant asthma with good safety, which has a certain clinical application value.